Mascc Score Calculator
Identify low-risk febrile neutropenia patients using the MASCC risk index. Enter values for instant results with step-by-step formulas.
Formula
MASCC Score = Burden of Illness + Hypotension + COPD + Tumor Type + Dehydration + Onset + Age (max 26)
The MASCC score sums weighted criteria: Burden of illness (mild=5, moderate=3, severe=0), No hypotension (+5), No COPD (+4), Solid tumor or no prior fungal infection (+4), No dehydration (+3), Outpatient onset of fever (+3), Age < 60 (+2). Score >= 21 indicates low risk. Maximum possible score is 26.
Worked Examples
Example 1: Low-Risk Solid Tumor Patient
Problem: A 45-year-old breast cancer patient on chemotherapy presents with fever of 38.5C and ANC of 350. She has mild symptoms, no hypotension, no COPD, no dehydration, and fever started at home.
Solution: Burden of illness (mild): +5\nNo hypotension (SBP >= 90): +5\nNo COPD: +4\nSolid tumor: +4\nNo dehydration: +3\nOutpatient onset: +3\nAge < 60: +2\nTotal MASCC Score: 26/26
Result: MASCC Score: 26 | Low Risk | Complication rate ~6% | May consider outpatient oral antibiotics
Example 2: High-Risk Hematologic Malignancy Patient
Problem: A 68-year-old AML patient presents with fever, moderate symptoms, hypotension (BP 82/50), and dehydration. Fever developed while inpatient.
Solution: Burden of illness (moderate): +3\nNo hypotension: No (0)\nNo COPD: +4\nSolid tumor: No (hematologic) (0)\nNo dehydration: No (0)\nOutpatient onset: No (inpatient) (0)\nAge < 60: No (0)\nTotal MASCC Score: 7/26
Result: MASCC Score: 7 | High Risk | Complication rate ~39% | Requires inpatient IV antibiotics and monitoring
Frequently Asked Questions
What is the MASCC score and what is it used for?
The MASCC (Multinational Association for Supportive Care in Cancer) score is a validated risk index used to identify low-risk patients with febrile neutropenia who may be suitable for outpatient management with oral antibiotics rather than requiring inpatient hospitalization with intravenous antibiotics. It was developed by Klastersky and colleagues in 2000 through a multinational prospective study of 1,139 episodes of febrile neutropenia. The score uses seven weighted clinical criteria to generate a composite score from 0 to 26 points, with a cutoff of 21 or higher defining low-risk patients. This tool has significantly changed the management paradigm for febrile neutropenia.
What does burden of illness mean in the MASCC score?
Burden of illness in the MASCC scoring system refers to the overall clinical severity at the time of presentation with febrile neutropenia, assessed by the treating physician. It is categorized into three levels: mild symptoms (5 points), which indicates the patient appears well with minimal symptoms beyond fever; moderate symptoms (3 points), indicating the patient is symptomatic but clinically stable; and severe symptoms (0 points), indicating the patient appears significantly ill with concerning clinical features such as rigors, respiratory distress, or hemodynamic instability. This subjective assessment captures clinical gestalt that laboratory values alone may not reflect and is one of the most heavily weighted components of the score.
What MASCC score indicates low risk for febrile neutropenia?
A MASCC score of 21 or higher (out of a maximum of 26) identifies patients as low risk for serious medical complications from febrile neutropenia. In the original validation study, patients with scores of 21 or above had a complication rate of approximately 6 percent and a mortality rate of less than 3 percent, compared to complication rates of 39 percent and mortality rates of 12 to 36 percent in high-risk patients scoring below 21. The positive predictive value for identifying low-risk patients was 91 percent, and the specificity was 68 percent. However, a MASCC score of 21 or higher alone is not sufficient to justify outpatient management without also considering other practical and clinical factors.
How does the MASCC score handle solid tumors versus hematologic malignancies?
The MASCC score awards 4 points for having a solid tumor (or no previous fungal infection in hematologic malignancy patients), reflecting the generally lower risk profile of febrile neutropenia in solid tumor patients compared to those with hematologic malignancies. Patients with hematologic malignancies such as leukemia or lymphoma tend to have more profound and prolonged neutropenia, higher rates of bacteremia, greater susceptibility to fungal infections, and worse outcomes from febrile episodes. This distinction is important because even with a technically low-risk MASCC score, patients with actively treated hematologic malignancies may require more cautious management due to their underlying disease biology and anticipated duration of neutropenia.
What are the limitations of the MASCC score?
The MASCC score has several important limitations. The burden of illness criterion is subjective and may vary between clinicians, reducing reproducibility. The score does not account for the expected duration of neutropenia, which is a critical determinant of infection risk. It was developed primarily in adult populations and may not be directly applicable to pediatric patients. The score does not incorporate microbiologic data, specific infection sites, or biomarkers such as procalcitonin that may improve risk stratification. Some studies have shown that the MASCC score misclassifies approximately 10 to 15 percent of patients as low risk who subsequently develop serious complications. Clinical judgment should always supplement the score.
What role does COPD play in the MASCC score?
The absence of chronic obstructive pulmonary disease (COPD) contributes 4 points to the MASCC score, making it one of the more heavily weighted criteria. COPD is included because patients with pre-existing lung disease are at significantly higher risk for respiratory complications during febrile neutropenia episodes, including bacterial pneumonia, respiratory failure, and the need for mechanical ventilation. COPD impairs mucociliary clearance and local immune defenses in the airways, creating a favorable environment for bacterial colonization and infection. Patients with COPD who develop febrile neutropenia have higher rates of documented respiratory infections and longer hospital stays compared to those without underlying lung disease.